DermBiont
Manufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
451 D St Ste 908, Boston, Massachusetts,...Website
www.dermbiont.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
2
1
1
1
1
About DermBiont
Pioneering the worlds leading precision dermatology company developing targeted topical therapeutics that address the root cause of skin diseasesExplore more
DermBiont Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is DermBiont your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once DermBiont has new funding data
Click to see if DermBiont had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Check if DermBiont has recently received funding, and reach out quickly before it becomes old news!
DermBiont, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when DermBiont launches new products
Congratulate Masked Content for being promoted to Masked Content at DermBiont
Check out if DermBiont is spiking on competitors!
Earning: See what the market has to say on DermBiont recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined DermBiont as Masked Content
Find 2 more new buyers
Compare Similar Companies to DermBiont
Compare insights from companies similar to DermBiont, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
DermBiont is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
DermBiont is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about DermBiont.
DermBiont financials insights
Gather financial insights about DermBiont, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$8M
2020
Debt
$150K
2021
Series A
$28M
2023
Series B
$35.2M
DermBiont Tech Stack
A closer look at the technologies used by DermBiont
Most Recent Scoops
Funding
Facilities Relocation / Expansion
DermBiont is planning to move offices in April 2024. The move will impact employees at the existing office located at 6425 Christie Avenue, Suite #255, Emeryville, CA.
Facilities Relocation/Expansion
Funding
Funding
DermBiont News & Media
DermBiont Announces 2024 Development Pipeline Update for its First-in-Class Targeted Topical Therapeutics for Seborrheic Keratoses, Basal Cell Carcinomas, and Melasma
BOSTON--(BUSINESS WIRE)--DermBiont, a clinical-stage biotechnology company that is advancing targeted topical therapeutics to address patient needs in three of the most frequently diagnosed dermatological indications, today announced updates on the company’s development pipeline, including the completion of enrollment in a Phase 2b clinical trial of SM-020 gel 1.0% for the treatment of SKs, and anticipated clinical milestones for 2024. “We are pleased to have completed enrollment in our CT-213DermBiont Announces First Close of $35.2 Million in a Series B Financing to Advance First-in-Class Targeted Topical Dermatological Therapeutics
BOSTON--(BUSINESS WIRE)--DermBiont, a clinical-stage biotechnology company that is advancing targeted topical therapeutics for the treatment of dermatological indications, today announced a $35.2 million Series B financing, including a $27.1 million Series B first close and $8.1 million in converting outstanding notes. Proceeds will be used to advance two drugs in development, SM-020, a topical novel AKT kinase inhibitor for the treatment of seborrheic keratoses (SKs), and SM-030, a topical novDermBiont Announces Positive Data from a Phase 2 Trial Treating Solar Lentigos and Normalizing Pigmentation of the Skin with 0.8% SM-030 Topical Gel
BOSTON--(BUSINESS WIRE)--DermBiont, a clinical-stage biotechnology company that is advancing targeted topical therapeutics for the treatment of dermatological indications, today announced positive data from its Phase 2 trial with 0.8% SM-030 gel, a product under development capable of regulating pigmentation by controlling the formation of new melanin. Disorders of hyperpigmentation, such as melasma, photoinduced hyperpigmentation, and solar lentigos (lentigines), are common skin conditions affDermBiont Presents Positive Phase 2 Trial Data Treating Seborrheic Keratosis with SM-020 Topical Gel at American Academy of Dermatology Annual Meeting
BOSTON--(BUSINESS WIRE)--DermBiont, a clinical-stage biotechnology company that is advancing targeted topical therapeutics for the treatment of a variety of dermatological indications, today announced that its Phase 2 adaptive design trial with of investigational drug SM-020 gel 1.0% met its primary endpoint of a one point improvement in Physician’s lesion assessment (PLA) score at last visit and safety via local tolerability, as well as key multiple secondary endpoints including complete clear
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding DermBiont
Sign Up For FreeTo access detailed company insights
Pioneering the worlds leading precision dermatology company developing targeted topical therapeutics that address the root cause of skin diseases... Read More
